Research Analysts Offer Predictions for TSE:FRX Q2 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Equities researchers at Wedbush raised their Q2 2026 EPS estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Friday, November 14th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will earn $0.55 per share for the quarter, up from their prior forecast of $0.52. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share.

Fennec Pharmaceuticals Trading Down 2.2%

TSE:FRX opened at C$12.17 on Monday. The firm has a market capitalization of C$342.18 million, a P/E ratio of -46.81 and a beta of 2.53. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. Fennec Pharmaceuticals has a one year low of C$5.68 and a one year high of C$13.83. The company’s 50-day simple moving average is C$12.14 and its 200 day simple moving average is C$11.57.

Insider Activity

In other news, insider Southpoint Capital Advisors Lp sold 26,900 shares of the business’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of C$13.23, for a total value of C$355,887.00. Following the sale, the insider directly owned 4,050,314 shares of the company’s stock, valued at C$53,585,654.22. The trade was a 0.66% decrease in their position. Insiders have sold 68,889 shares of company stock worth $900,406 in the last ninety days. 16.20% of the stock is currently owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.